Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Neurofibromatosis Type 2 (Randomized Double-blind Trial)
jRCT2080224914Phase 2Not yet recruiting
- Sponsor
- Kiyoshi Saito
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neurofibromatosis type 2 (NF2) and acoustic neuroma comparing Bevacizumab with Placebo (normal saline) (2 arms). Planned start Oct 2019; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
neurofibromatosis type 2 (NF2)acoustic neuroma
Beyond the preview
Go deeper on jRCT2080224914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224914.